Synairgen has successfully raised US$114 million to support phase III trial of COVID candidate
Synairgen plc has completed its oversubscribed equity fundraising to raise US$114 million to fund a phase III trial for 900 patients for the effects of its SNG001 drug on patients with COVID-19. In addition, the raise will be used to scale up manufacturing and device activities.
Synairgen engages in the provision of respiratory drug discovery and development. It focuses on severe asthma, chronic obstructive pulmonary disease and severe viral infections, as well as COVID-19. The company was founded by Donna E. Davies, Ratko Djukanovic, and Stephen T. Holgate in June 2003 and is headquartered in Southampton.
Oaklins Cavendish’s sister firm finnCap, based in the UK, acted as advisor to Synairgen plc in this transaction.
CEO, Synairgen plc
Talk to the deal team
Aenza S.A.A. has completed a follow-on
Aenza S.A.A. has completed af follow-on to prepay part of a recently renegotiated bridge loan.Learn more
move UP has been acquired by Acture B.V.
move UP Gesellschaft für Gesundheitsmanagement mbH, an innovative provider of holistic corporate health management solutions, has been acquired by Acture B.V., a leader in welfare management. This acquisition represents a major step in Acture’s plans to expand into the German corporate health management sector.Learn more
Pampa Camarones has completed an IPO
Pampa Camarones SpA has successfully raised US$5 million through its stock market debut on ScaleX (Santiago Venture Exchange). These funds will be used to extend the mine life and incorporate the high-grade polymetallic project, Ciclón Exploradora.Learn more